Roche receives FDA approval for Cytomegalovirus viral load test
Published on Thursday, 05 July 2012 13:57 Written by TradersHuddle Staff
First FDA-approved laboratory test for quantifying DNA of potentially deadly virus helps physicians manage organ transplant patients on antiviral therapy
PLEASANTON, Calif., July 5, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for a new test to assess a patient's viral load of cytomegalovirus (CMV). The fully automated COBAS® AmpliPrep / COBAS® TaqMan® CMV Test is the first FDA-approved laboratory test for use in quantifying CMV DNA in human plasma specimens. Physicians use CMV DNA viral load information from the test to help manage patients who have been diagnosed with CMV disease, specifically patients whose immune system has been suppressed for solid organ transplantation.
"We are pleased to offer this innovative test to address a key medical need for immunosuppressed solid organ transplant patients," said Paul Brown, Ph.D., head of Roche Molecular Diagnostics. "With this test, laboratories now have an FDA-approved option for standardized and automated CMV viral load testing that improves the laboratory's workflow. It provides physicians with clinically useful information to aid in the management of solid organ transplant patients with CMV disease."
Roche's new real-time polymerase chain reaction (PCR)-based CMV test is designed for use on the fully automated COBAS® AmpliPrep/COBAS® TaqMan® System, an established platform for viral load monitoring of multiple infectious diseases. The system can be combined with the cobas p 630 Instrument, which provides an integrated pre-analytical primary tube handling solution.
Roche expects to begin shipping the new CMV test kit in the U.S. in August 2012.
About the test
The COBAS® AmpliPrep / COBAS® TaqMan® CMV Test is intended for use as an aid in the management of solid-organ transplant patients who are undergoing anti-CMV therapy. In this population, the test can be used to assess virological response to antiviral treatment. The test is traceable to the first WHO International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques (NIBSC 09/162) and reliably monitors cytomegalovirus (CMV) infections.
About the COBAS AmpliPrep/COBAS TaqMan System
Roche's fully automated COBAS® AmpliPrep/COBAS TaqMan® System combines the COBAS AmpliPrep Instrument for automated sample preparation and the COBAS® TaqMan® Analyzer or the smaller COBAS TaqMan 48 Analyzer for automated real-time PCR amplification and detection. The COBAS AmpliPrep/COBAS TaqMan® System has parallel processing with other key molecular diagnostics assays targeting medically relevant diseases (Hepatitis B virus, Hepatitis C virus, and Human Immunodeficiency Virus). Roche's AmpErase enzyme is also included in each test and is designed to prevent cross-contamination of samples and labs.
CMV is the most common and important viral infection in solid organ transplant (SOT) recipients. The virus can be transmitted through the donor organ, resulting in CMV infection and leading to the development of CMV disease, or can occur by reactivation of the virus in transplant recipients with previous CMV infection. CMV disease in transplant recipients may be similar to infectious mononucleosis with fever, malaise and mild laboratory abnormalities, or can be more serious with involvement of the lung or gastrointestinal tract. Between 50 – 80% of all people in the US become infected with CMV. Although healthy persons usually have few symptoms at the time of initial infection, after infection the virus remains in a latent state in the body for the rest of a person's life. The virus can then be transmitted and cause infection through organ donation, or latent virus in the transplant recipient can become reactivated and cause symptomatic disease.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information please contact Roche Molecular Systems at 925-730-8114
- Roche and Isis Pharmaceuticals form alliance for Huntington's disease
- Tucson Symposium attracts over 450 global scientists focused on personalized healthcare
- Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesions
- Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin® for acromegaly and neuroendocrine tumors
- RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
Related Partner Headlines
- FDA Approves Lucentis (Ranibizumab Injection) for Treatment of Diabetic Macular Edema - Benzinga
- Roche Submits TnT-hs Assay to FDA for Clearance on the Cobas Immunoassay and Elecsys Analyzers - Benzinga
- From Yesterday, Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus Chemotherapy - Benzinga
- From Earlier: Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection - Benzinga
- Roche's Ventana Receives FDA Approval of INFORM HER2 Dual ISH Assay on the BenchMark ULTRA - Benzinga
- Roche Announces FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer - Benzinga
- Roche Receives FDA Clearance for Test to Screen and Diagnose Chlamydia and Gonorrhea Infection in Symptomatic and Asymptomatic Patients - Benzinga
- Roche Announces FDA Approves Erivedge Capsule, the First Medicine for Adults with Advanced Basal Cell Carcinoma - Benzinga
Latest Partner Headlines
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com
Gap Up and Sit - TheStreet.com
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com
Windows 8 PC Sales Disappointing: Report - TheStreet.com
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Dow JonesCompany ID [INDEXDJX:.DJI] Last trade:15,294.50 Trade time:4:53PM EDT Value change:▼12.67 (-0.08%)
S&P 500Company ID [INDEXSP:.INX] Last trade:1,650.51 Trade time:4:52PM EDT Value change:▼4.84 (-0.29%)
NASDAQCompany ID [INDEXNASDAQ:.IXIC] Last trade:3,459.42 Trade time:5:15PM EDT Value change:▼3.88 (-0.11%)
In The Wires
Foot Locker, Inc. Reports First Quarter Results
DISH pursues Co-Development of Fixed-Mobile Broadband Offering
Star Gold Announces Exercise of Warrants
Destination XL Group, Inc. Reports First-Quarter 2013 Financial Results
PacSun Brings The Latest Brands And Trends Inspired By The California Lifestyle To SoHo As Part Of Summer Pop-Up Store
Cato 2013 Annual Meeting Highlights
Yingli Green Energy to Supply 10.269 MW Modules for the Largest Single Site PV Power Plant in Malaysia
China Biologic Comments on the Proposed Shanghai RAAS Transaction